Ppp1r3d Activators
Chemical activators of PPP1R3D work by modulating various signaling pathways and enzyme activities, leading to changes in the phosphorylation state of this protein. Insulin, for instance, initiates a signaling cascade that includes the activation of PI3K and PKB/Akt, resulting in the dephosphorylation and consequent activation of PPP1R3D. Similarly, IGF-1 engages its receptor to activate Akt, which also promotes PPP1R3D activation by enhancing its dephosphorylation state. Compounds that inhibit protein phosphatases, such as okadaic acid and calyculin A, can indirectly activate PPP1R3D. They do this by selectively inhibiting PP2A more strongly than PP1 at lower concentrations, which shifts the balance towards PP1 activity, resulting in increased PPP1R3D activity.
Other chemicals operate by influencing cyclic nucleotide levels. Forskolin and cilostamide, by activating adenylate cyclase and inhibiting phosphodiesterase 3 respectively, cause an elevation in cAMP levels, which enhances PKA activity. PKA can then phosphorylate and inhibit the regulators of PP1, reducing their suppressive effects on PPP1R3D. Milrinone acts in a similar manner to cilostamide by elevating cAMP levels. Moreover, roscovitine, by inhibiting cyclin-dependent kinases, may alter the balance of kinase and phosphatase activities favoring PPP1R3D activation. PDE5 inhibitors such as sildenafil and zaprinast primarily raise cGMP levels, which can indirectly influence cAMP pathways and thus PKA activity, leading to PPP1R3D activation. Additionally, dipyridamole and vinpocetine, by inhibiting phosphodiesterase enzymes, can increase cAMP and cGMP levels, which might enhance PKA and PKG activity, respectively, and promote the activation of PPP1R3D.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin activates protein phosphatase 1 regulatory subunit 3D (PPP1R3D) by promoting dephosphorylation through the insulin signaling pathway, which includes activation of the phosphatidyl-inositol-3-kinase (PI3K) and protein kinase B (PKB/Akt) leading to the activation of PPP1R3D. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A, but at low concentrations, it can preferentially inhibit PP2A, leading to a relative increase in PP1 activity, thereby indirectly activating PPP1R3D. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Similar to okadaic acid, calyculin A inhibits both PP1 and PP2A, but with a stronger effect on PP2A at lower concentrations, which can result in the indirect activation of PPP1R3D due to the increased relative activity of PP1. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of phosphodiesterase 3 (PDE3) that increases cAMP levels by preventing its breakdown, leading to activation of PKA, which can subsequently activate PPP1R3D through reduced inhibition. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is another PDE3 inhibitor that functions similarly to cilostamide by increasing cAMP levels, hence enhancing PKA activity and potentially activating PPP1R3D through diminished inhibition. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a cyclin-dependent kinase inhibitor that may lead to changes in phosphorylation states of various proteins, indirectly leading to the activation of PPP1R3D by altering the balance of kinase and phosphatase activities. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is another PDE5 inhibitor that increases cGMP levels, which might have crossover effects on cAMP signaling, impacting PKA activity and thereby activating PPP1R3D. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole inhibits phosphodiesterase enzymes and can increase cAMP levels, subsequently activating PKA, which may lead to the activation of PPP1R3D by reducing the inhibitory effect of PKA on PP1. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine inhibits PDE1 and can increase cAMP and cGMP levels, which can enhance PKA and PKG activity, respectively, potentially leading to the activation of PPP1R3D through downstream dephosphorylation events. | ||||||